NCT03268382View on ClinicalTrials.gov

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

July 10, 2019

Study Completion Date

July 10, 2019

Conditions
High-grade Serous Ovarian Cancer
Interventions
DRUG

APR-246

Intravenous infusion

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

Intravenous infusion

Trial Locations (12)

9000

Medische oncologie, Universitair Ziekenhuis Gent, Ghent

28040

Hospital Universitario Fundación Jiménez Díaz, Madrid

28050

Hospital Universitario HM Sanchinarro, Madrid

46010

Hospital Clinico Universitario de Valencia, Valencia

B-3000

Leuven University Hospitals, Leuven

B-4000

Centre Hospitalier Universitaire de Liège, Liège

08916

Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona

08035

Hospital Vall d'Hebron, Barcelona

CB2 0QQ

Cambridge Cancer Trials Centre, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge

EH4 2XR

Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh

SM2 5PT

The Royal Marsden NHS Foundation Trust, London

W12 0NN

Imperial College London, Hammersmith Hospital Campus, London

Sponsors

Lead Sponsor

Aprea Therapeutics
All Listed Sponsors
lead

Aprea Therapeutics

INDUSTRY